<section xmlns="http://xml.house.gov/schemas/uslm/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" style="-uslm-lc:I80" id="id6f61d953-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r"><num value="387r">§ 387r.</num><heading> Drug products used to treat tobacco dependence</heading><subsection style="-uslm-lc:I19" class="indent2 firstIndent-2" id="id6f61d954-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r/a"><num value="a" class="bold">(a)</num><heading class="bold"> In general</heading><chapeau>The Secretary shall—</chapeau><paragraph style="-uslm-lc:I12" class="indent1" id="id6f61d955-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r/a/1"><num value="1">(1)</num><content> at the request of the applicant, consider designating products for smoking cessation, including nicotine replacement products as fast track research and approval products within the meaning of <ref href="/us/usc/t21/s356">section 356 of this title</ref>;</content>
</paragraph>
<paragraph style="-uslm-lc:I12" class="indent1" id="id6f61d956-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r/a/2"><num value="2">(2)</num><content> consider approving the extended use of nicotine replacement products (such as nicotine patches, nicotine gum, and nicotine lozenges) for the treatment of tobacco dependence; and</content>
</paragraph>
<paragraph style="-uslm-lc:I12" class="indent1" id="id6f61d957-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r/a/3"><num value="3">(3)</num><content> review and consider the evidence for additional indications for nicotine replacement products, such as for craving relief or relapse prevention.</content>
</paragraph>
</subsection>
<subsection style="-uslm-lc:I19" class="indent2 firstIndent-2" id="id6f61d958-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r/b"><num value="b" class="bold">(b)</num><heading class="bold"> Report on innovative products</heading><paragraph style="-uslm-lc:I79" class="indent3 firstIndent-2" id="id6f61d959-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r/b/1"><num value="1" class="bold">(1)</num><heading class="bold"> In general</heading><chapeau>Not later than 3 years after <date date="2009-06-22">June 22, 2009</date>, the Secretary, after consultation with recognized scientific, medical, and public health experts (including both Federal agencies and nongovernmental entities, the Institute of Medicine of the National Academy of Sciences, and the Society for Research on Nicotine and Tobacco), shall submit to the Congress a report that examines how best to regulate, promote, and encourage the development of innovative products and treatments (including nicotine-based and non-nicotine-based products and treatments) to better achieve, in a manner that best protects and promotes the public health—</chapeau><subparagraph style="-uslm-lc:I13" class="indent2" id="id6f61d95a-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r/b/1/A"><num value="A">(A)</num><content> total abstinence from tobacco use;</content>
</subparagraph>
<subparagraph style="-uslm-lc:I13" class="indent2" id="id6f61d95b-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r/b/1/B"><num value="B">(B)</num><content> reductions in consumption of tobacco; and</content>
</subparagraph>
<subparagraph style="-uslm-lc:I13" class="indent2" id="id6f61d95c-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r/b/1/C"><num value="C">(C)</num><content> reductions in the harm associated with continued tobacco use.</content>
</subparagraph>
</paragraph>
<paragraph style="-uslm-lc:I79" class="indent3 firstIndent-2" id="id6f61d95d-6123-11e3-9d46-8388bf8dcc60" identifier="/us/usc/t21/s387r/b/2"><num value="2" class="bold">(2)</num><heading class="bold"> Recommendations</heading><content><p style="-uslm-lc:I12" class="indent1">The report under paragraph (1) shall include the recommendations of the Secretary on how the Food and Drug Administration should coordinate and facilitate the exchange of information on such innovative products and treatments among relevant offices and centers within the Administration and within the National Institutes of Health, the Centers for Disease Control and Prevention, and other relevant agencies.</p>
</content>
</paragraph>
</subsection>
<sourceCredit id="id6f61d95e-6123-11e3-9d46-8388bf8dcc60">(<ref href="/us/act/1938-06-25/ch675/s918">June 25, 1938, ch. 675, § 918</ref>, as added <ref href="/us/pl/111/31/s101/b/3">Pub. L. 111–31, div. A, title I, § 101(b)(3)</ref>, <date date="2009-06-22">June 22, 2009</date>, <ref href="/us/stat/123/1825">123 Stat. 1825</ref>.)</sourceCredit>
<notes type="uscNote" id="id6f61d95f-6123-11e3-9d46-8388bf8dcc60">
<note style="-uslm-lc:I74" topic="miscellaneous" id="id6f61d960-6123-11e3-9d46-8388bf8dcc60"><heading class="centered smallCaps">Modification of Deadlines for Secretarial Action</heading><p style="-uslm-lc:I21" class="indent0">With respect to any time periods specified in an amendment by div. A of <ref href="/us/pl/111/31">Pub. L. 111–31</ref> that begin on <date date="2009-06-22">June 22, 2009</date>, within which the Secretary of Health and Human Services is required to carry out and complete specified activities, with certain limitations, the calculation of such time periods shall commence on the first day of the first fiscal quarter following the initial 2 consecutive fiscal quarters of fiscal year 2010 for which the Secretary has collected fees under <ref href="/us/usc/t21/s387s">section 387s of this title</ref>, and the Secretary may extend or reduce the duration of one or more such time periods, except that no such period shall be extended for more than 90 days, see <ref href="/us/pl/111/31/s6">section 6 of Pub. L. 111–31</ref>, set out as a note under <ref href="/us/usc/t21/s387">section 387 of this title</ref>.</p>
</note>
</notes>
</section>